What the July 2026 FDA Cancer Approvals Mean

In brief

The FDA's oncology approval list had several notable updates in mid-July 2026. The approvals involved different situations: hormone receptor-positive breast cancer, RET fusion-positive solid tumors, muscle-invasive bladder cancer, and multiple myeloma.

That variety is the main story. Modern cancer approvals are increasingly specific. They are tied to tumor subtype, biomarkers, prior treatment, surgery plans, route of administration, or a particular combination of medicines.

What happened

The FDA posted several oncology approval notices during the week of July 9-14, 2026.

• Gedatolisib, marketed as Revtorpyk, was approved with fulvestrant, with or without palbociclib, for certain adults with HR-positive, HER2-negative, locally advanced or metastatic breast cancer after endocrine therapy. The FDA notice specifies a group without a PIK3CA mutation.
• Selpercatinib, marketed as Retevmo, received traditional approval for adults and children age 2 and older with advanced or metastatic solid tumors that have a RET gene fusion, after prior systemic treatment or when no satisfactory alternative treatment options exist.
• Pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, each with enfortumab vedotin, was approved before and after cystectomy for adults with muscle-invasive bladder cancer.
• Isatuximab-irfc and hyaluronidase-fihj was approved as a subcutaneous formulation for multiple myeloma indications in which isatuximab is used with other medicines.

Each notice has its own trial evidence, safety information, dosing details, and prescribing label. A roundup is useful because it shows the shape of the week, but the real clinical meaning lives in the details of each approval.

Why this is notable

These approvals point to four different trends in cancer care.

First, breast cancer treatment continues to split into narrower groups based on hormone receptors, HER2 status, tumor genetics, and prior therapy. A new approval may help one defined group without changing care for another.

Second, tumor-agnostic treatment is becoming more familiar. In a tumor-agnostic approval, the key feature is a molecular change, such as a RET fusion, rather than only the organ where the cancer started.

Third, some bladder cancer regimens are moving into treatment given around surgery. In this case, the FDA notice describes treatment before cystectomy and then after surgery, not a replacement for surgery.

Fourth, some approvals are about how a medicine is given. A subcutaneous formulation may make administration different from an intravenous infusion, but it still has to be used in the approved combinations and settings.

What this does not mean

• It does not mean these medicines are right for everyone with breast cancer, bladder cancer, multiple myeloma, or any solid tumor.
• It does not mean a person should stop, delay, or change treatment without talking with their oncology team.
• It does not mean a biomarker-targeted medicine works unless the relevant biomarker is present and the patient's situation matches the approved use.
• It does not mean the newest approval is always better than an established standard for a particular person.
• It does not remove the need to understand side effects, drug interactions, insurance coverage, and treatment goals.

How to read an approval notice

An FDA oncology approval is not a single sentence. It includes an indication, the patient group, the trial or evidence base, the main benefit measured, common side effects, serious risks, and dosing.

When reading one, look for:

• the cancer type and stage;
• the biomarker or subtype, if any;
• whether the approval is for first treatment, later treatment, before surgery, after surgery, or maintenance;
• the comparator or control group in the study;
• whether the result measured tumor shrinkage, time before cancer grew, survival, symptoms, or another outcome;
• the important safety warnings.

Questions to ask a healthcare team

• Does this approval apply to my exact cancer type, stage, and biomarker results?
• Would I need additional biomarker testing before this could matter?
• Is this option part of standard care now, or would it be considered later?
• What side effects are most important for me to understand?
• Will insurance coverage or prior authorization affect access?

Sources

This article was written from the sources below, which were checked on July 18, 2026.

• U.S. Food and Drug Administration. Oncology/Cancer/Hematologic Malignancies Approval Notifications.
• U.S. Food and Drug Administration approval notices for gedatolisib, selpercatinib, pembrolizumab with enfortumab vedotin, and isatuximab-irfc with hyaluronidase-fihj.
• National Cancer Institute background pages on cancer treatment, targeted therapy, and immunotherapy.

How this article was prepared

Prepared by Cancer Explained's AI-assisted editorial system and checked against the sources listed below. This article has not been reviewed by a healthcare professional unless a named reviewer is specifically shown.

Cancer Explained is published by the National Cancer Information Foundation as a nonprofit-oriented public-interest education project. It is not a diagnostic service, does not recommend treatments, and is not for emergencies.

Found an error, a broken source link, outdated information, or wording that feels unsafe or unclear? Report it here - we log and act on material corrections.